Angiogenesis Inhibitors

Slides:

Advertisements

Similar presentations

Supplementary Figure 1 Select oncogenic target of interest Choose an oncogene-driven cell line and a cell line to be used as a counterscreen OCI-AML3 Ba/F3-NRAS-G12D.

Advertisements

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Article Title: AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies Journal.

Disease B A C SUPPLEMENTARY FIGURE 1 Molecular Function D.

Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b

The reading is 7.38 mm. The reading is 7.72 mm.

Supplemental Figure 1. Scatter plot of a PANC1 3D sphere CellTiterGlo assay plate. Each dot refers to the activity of a compound in a 1536-well microplate.

Figure S2 apoptosis-PARP -WB

Ctrl IR, 2h G2 P53 Ser15 S G1 G2 S G1 Figure S1. The bivariate (phospho-p53 Ser15 vs DNA content) distribution of control and irradiated with 6 Gy mESCs.

ABAE positive cells 6h after treatment

SIOP-E HR-MBL Hungarian Proposal

Figure 3 3-MA does not inhibit the formation of autophagosomes induced by ZnPPIX HeLa cells were pre-incubated with either 0.1% DMSO (control) or 10 mM.

Date of download: 1/1/2018 Copyright © ASME. All rights reserved.

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

a b c ** ** ** ** * * * P450arom mRNA Trascript Levels (Fold)

Chemical Genetic Modifier Screens

A 4 Band intensity (relative unit) MMP-9 MMP-2 B C 4 4

Chemosensitivity linked to p73 function

Supplementary Figure 1 Oligomycin, 1µM FCCP,

Mitophagy is independent of PINK1 and Parkin.

A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non–Small-Cell Lung Cancer Steven.

Volume 14, Issue 2, Pages (August 2008)

Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.

Supplemental Information

Scratch n’ Screen for Inhibitors of Cell Migration

A B Supplementary Figure 3

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

A B MCF7-ERaWT MCF7-ERaY537S MCF7-ERaY537N MCF7-ERaY537C MCF7-ERaD538G

Volume 28, Issue 4, Pages (October 2015)

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Supplementary Figure S2

Supplementary Figure text

Supplemental Figure 1A – I

Biofilm Inhibitors that Target Amyloid Proteins

Volume 19, Issue 7, Pages (July 2012)

Supplementary Table 1.

8 slides for 4 panels (A-D)

Volume 11, Issue 6, Pages (June 2007)

Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D

Flavonoid DAPI Mitotracker

Identification of p21 inhibitors to enhance chondrogenesis in osteoarthritic synovial mesenchymal progenitor cells K.L. Bertram, T. Irvine, P. Tailor,

MITF upregulation leads to Hsp90i resistance

Volume 8, Issue 24, Pages R896-R897 (December 1998)

A C D B Asynchronous nM Nocodazole 150 ► 100 ► 75 ►

Supplementary Figure 1. A

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

HeLa COS-7 Supplementary Figure S1 Coelho et al (2014) MM pSPL3 MM

Supplementary Figures

Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron Transport Jing Xu.

Supplementary Figure 1 ** ** _ _ + + a. b. ** ** _ _ + + c. n=3 RU486

Volume 22, Issue 2, Pages (February 2015)

Effect of RGS4 inhibitor, CCG50014 on the formalin-induced nociceptive responses in the RGS4-knockout mice A B Supplement. 1↑

Volume 17, Issue 1, Pages (January 2010)

Leto et al., Supplementary Figure S3

A B Supplementary Figure S1 PC3 cells Vehicle 3β-Adiol

A B C D Supplementary Figure S1 UMSCC1 Plateau: 24 hr Pre-Treatment

HCT-15 HT-29 * Figure S1. Oxaliplatin treatment increases CD44high subpopulations in both HCT-15 and HT-29 cells. Flow.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Regulation of FoxB expression.

Methimazole Is an Inhibitor of Melanin Synthesis in Cultured B16 Melanocytes Behrooz Kasraee, Ambros Hügin, Christian Tran, Olivier Sorg, Jean-Hilaire.

Motoneuron numbers (mean ± SEM) in 48 hr control cultures (open bar) and in cultures treated with either 100 nm thrombin (hatched bars), 1 μm YVAD-CHO,

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

a b 10A.zp85WT 10A.zp85S83μ 10A.vec 10A.z 10A.vec 10Az 10Az.p85WT

Activation of CHOP and DR5 by DIM-C-pPhtBu.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

Syrosingopine is synthetic lethal with mitochondrial ETC inhibition

Presentation transcript:

Angiogenesis Inhibitors Supplementary Figure 1 A Supplementary Figure 2 A B Angiogenesis Inhibitors EpI Screen

SKOV3 DMSO Vorinostat Mocetinostat Entinostat 500 nM 5 mM Supplementary Figure 3 SKOV3 DMSO Vorinostat Mocetinostat Entinostat 2.7 5.7 6.1 4.7 500 nM 1.0 1.7 4.1 3.1 92.1 87.5 85.6 87.2 5.0 11.2 12.7 8.3 5 mM 0.7 7.3 11.3 6.9 88.5 74.8 71.3 79.1

T24 DMSO Vorinostat Mocetinostat Entinostat 500 nM 5 mM Supplementary Figure 3 (cont’d) T24 DMSO Vorinostat Mocetinostat Entinostat 10.2 9.9 23.3 18.6 500 nM 2.6 2.8 8.1 4.7 83.0 80.9 65.0 71.3 6.6 15.8 16.0 12.7 5 mM 1.6 11.0 33.5 14.5 85.8 68.8 48.2 68.5

Supplementary Figure 4 A B C 24 96 (Hr) DMSO or HDACi Treatment 24 96 (Hr) DMSO or HDACi Treatment Cell Plating MTS Assay 48 Taxol B C